(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease.
Early Alzheimer’s patients who completed their course…
Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118877
Author :
Publish date : 2025-12-07 19:18:00
Copyright for syndicated content belongs to the linked Source.
